Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer

• Main Authors: Michiko Nonaka (Author), Seiya Sato (Author), Daiken Osaku (Author), Mayumi Sawada (Author), Akiko Kudoh (Author), Jun Chikumi (Author), Shinya Sato (Author), Tetsuro Oishi (Author), Tasuku Harada (Author)
• Format: Book
• Published: Elsevier, 2018-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bevacizumab (Bev) is an antiangiogenic drug used to treat various malignances, including ovarian cancer (OC). Bev is generally well-tolerated; however, it has a characteristic toxicity profile. In particular, gastrointestinal perforation (GIP) is a rare but serious side effect that can be lethal. A...